Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

[News]

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

More... (http://www.news-medical.net/news/20100719/Geron-commences-enrollment-in-imetelstat-Phase-2-clinical-trial-for-NSCLC.aspx)